Why the study?
Does inhibition of NLRP3 prevent atrial fibrillation?
Does inhibition of NLRP3 prevent atrial fibrillation?
Inhibition of the NLRP3 inflammasome in cardiomyocytes represents a potential novel therapeutic approach for atrial fibrillation.
NLRP3 inhibition merits testing for AF prevention; leaves open clinical translation from animal models.
Our study establishes a novel pathophysiological role for CM NLRP3 inflammasome signaling, with a mechanistic link to the pathogenesis of AF, and establishes the inhibition of NLRP3 as a potential novel AF therapy approach.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: